Union City, California, -based Abaxis (ABAX), a company that manufactures and sells portable blood analysis systems for human and veterinary uses, has seen its stock corrected almost 25% from the top it created at $51.84 in July. Currently the stock is consolidating around $40 and looks dirt-cheap post correction. In this investment thesis I will explain why investors should consider accumulating the stock in this corrective phase. I expect the stock to rise ~50% from the current level over the next 12 months, against a very limited downside of not more than 5%.
Abaxis is famous for its blood constituent measurement devices. Its point-of-care blood chemistry analyzer systems are used extensively in human medical and veterinary...
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: